genta_8k-042111.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
 

 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  April 21, 2011
 
GENTA INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
 
 
Delaware
 
 
(State or Other Jurisdiction of Incorporation)
 
 
0-19635
 
33-0326866
(Commission File Number)
 
(IRS Employer Identification No.)
 
200 Connell Drive
Berkeley Heights, NJ
 
07922
(Address of Principal Executive Offices)
 
(Zip Code)
 
 
(908) 286-9800
 
(Registrant’s Telephone Number, Including Area Code)
 
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant
under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre -commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre -commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 
 

 

Item 8.01 Other Events.

On April 21, 2011, Genta Incorporated updated its formal guidance for release of results from its Phase 3, randomized, controlled trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma, also known as the AGENDA trial.   After completion of final data collection, transfer and locking of the database, and statistical analysis, the Company expects to release a “top-line” statement regarding the result for overall survival in May 2011.  The data collection process for this double-blind trial has not yet been completed.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number
 
Description
 
99.1
 
Press Release of the Company dated April 21, 2011
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
   
GENTA INCORPORATED
Date:
April 21, 2011
 
By:
/s/ GARY SIEGEL
       
Name:
Gary Siegel
       
Title:
Vice President, Finance